Reply  by Olsen, Stephanie L. et al.
1400 LETTERS TO THE EDITOR JACC Vol. 26, No. 5 
November 1,1995:1399-401 
Although this is an elegant study conducted in a prospective, 
randomized, ouble-blind, placebo-control manner, there are some 
issues of concern. The findings at baseline revealed more patients 
with New York Heart Association functional class III and with 
higher norepinephrine l vels in the carvedilol group. Limited 
information about concomitant therapy at baseline is provided. It 
seems pertinent to evaluate the type and dosage of angiotensin- 
converting enzyme inhibitors and diuretic and antiarrhythmic drugs 
used at baseline. Even more important, was there any subsequent 
adjustment in concomitant therapy after randomization, particu- 
larly among patients randomized to receive carvedilol? Although 
most of these differences at baseline between the groups did not 
reach statistical significance, their potential effect on outcome has 
to be strongly considered, particularly at later stages during the 
course of the study. Detailed evaluation of these variables eems 
justified in light of the apparent favorable ffects of carvedilol on 
the various variables described in the report. 
There was an impressive increase in left ventricular ejection 
fraction of 52% in the group receiving carvedilol. However, it is not 
clear whether this marked improvement was due to an inotropic effect 
of the drug (unlikely) or to a decrease in heart rate with a resultant 
increase in stroke volume. Furthermore, more patients in the group 
receiving carvedilol had ischemic ardiomyopathy. In such patients it is 
possible that a favorable anti-ischemic effect from carvedilol could 
have resulted in improved myocardial contractility. 
During submax exercise treadmill testing at 4-month follow up, the 
carvedilol group had a greater increase in exercise duration. However, 
at baseline patients receiving carvedilol seem to have exercised for a 
shorter time during submax exercise treadmill testing than patients 
receiving placebo. This finding is not addressed in more detail. Could 
the shorter exercise duration during submax exercise treadmill testing 
at baseline indicate worse heart failure in this group? This is an 
important question because other variables, such as adjustment of 
concomitant therapy, could have influenced the result seen during the 
follow-up submax exercise treadmill testing. 
Olsen et al. conclude that in patients with heart failure as a result 
of ischemic or idiopathic dilated cardiomyopathy, treatment with 
carvedilol results in a significant improvement in rest left ventricular 
function and lessening of symptoms of heart failure. However, thc 
issues raised suggest a need for a closer look at some variables before 
more definitive conclusions are reached regarding the potential favor- 
able effects of carvedilol in patients with heart failure. 
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Carvedilol Therapy in Heart Failure--III 
A recent report by Olsen et al. (1) demonstrating improvement of
left ventricular function and symptoms in chronic heart failure with 
carvedilol therapy provides further good evidence of the usefulness 
of beta-adrenergic blocking agents in chronic heart failure. The 
data suggest hat a reduction in heart rate and rate-pressure 
product are the most important factors for hemodynamic and 
symptomatic mprovement after such treatment. In 1978, at the 
International Symposium of Beta-Adrenergic Blockade, I stated 
that "in some selected cases of resistant chronic heart failure with 
tachycardia the addition of low-dose beta-adrenergic blocking 
agents may be useful, and that further study is warranted" (2). I 
would like to pose the following questions: 
1. Is it necessary to increase beta-blockers to the target doses if the 
rest heart rates are reduced to -65 beats/rain? 
2. Do the vasodilator properties of carvedilol provide additional benefit if
the patients are also receiving adequate doses of vasodilator drugs? 
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Reply 
Ghali and Carbajal observe that the carvedilol group may have had a 
higher prevalence of advanced heart failure at baseline. To determine 
whether these differences affected our results, we stratified the subjects 
in two ways: 1) by baseline New York Heart Association functional 
class and 2) by baseline plasma norepinepfirine concentrations, with 
subjects divided at the median value of 337 pg/ml. There were no 
significant differences in the magnitude of change with carvedilol 
therapy between study subsets for any variable that we originally 
observed to improve with carvedilol for all subjects. In addition, we 
compared the response to carvedilol versus the response to placebo for 
each of the subject subsets. Improvements were observed with carve- 
dilol therapy that were significantly different from placebo in all four 
subsets for left ventricular ejection fraction, left ventricular f actional 
shortening, heart rate, stroke volume index and left ventricular stroke 
work index. For example, left ventricular ejection fraction (LVEF) 
improved with carvedilol therapy compared with placebo in subjects 
with either function class II symptoms (ALVEF = 0.12 + 0.02 for 
carvedilol; ALVEF = 0.01 -+ 0.2 for placebo, p = 0.0021) or class III 
symptoms (ALVEF = 0.08 -+ 0.02 for carvedilol; ALVEF = -0.01 -+ 
0.02 for placebo, p = 0.0014). Thus, it does not appear that he differences 
between the response to carvedilol and placebo can be attributed to 
differences ineach treatment group's baseline characteristics. 
During the course of the study, no subject received an increase in 
their dose of angiotensin-converting enzyme inhibitor or vasodilator. 
Some subjects had decreases in diuretic dose during up-titration of 
study medication when symptomatic orthostatic hypotension was ob- 
served. It seems unlikely that such small changes in concomitant 
medications can account for our findings. 
Carbajal speculates that the response to carvedilol may have 
resulted from the addition of an antianginal gent in subjects with 
active myocardial ischemia. However, none of our subjects devel- 
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oped angina or electrocardiographic changes of ischemia on exer- 
cise testing. In addition, subjects with idiopathic dilated cardiorny- 
opathy had greater hemodynamic and exercise improvements with 
carvedilol than subjects with ischemic ardiomyopathy. These find- 
ings suggest hat carvedilol's mechanisms for improving left ven- 
tricular function are more complex than a simple, direct anti- 
ischemic action. 
Lee poses two questions. Our empiric observations suggest that 
it is easier to initiate therapy with beta-blockers with vasodilator 
properties uch as carvedilol than those without these actions. 
However, there currently are no prospective, randomized studies to 
confirm this opinion. The response to carvedilol appears to be indepen- 
dent of rest heart rate. For example, there was no difference in the 
response to carvedilol when subjects were stratified at the median heart 
rate (ALVEF = 0.11 _+ 0.03 for heart rate 64 to 80 beats/rain; ALVEF = 
0.10 -+ 0.02 for heart rate 82 to 125 beats/rain). Further information 
regarding the dose-response of carvedilol will be forthcoming from the 
recently completed Multicenter Oral Carvedilol Heart Failure Assess- 
ment (MOCHA) trial. 
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